Chemotherapy of leishmaniasis: present challenges
Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
Leishmania–macrophage interactions: Insights into the redox biology
Leishmaniasis is a neglected tropical disease that affects about 350 million individuals
worldwide. The protozoan parasite has a relatively simple life cycle with two principal …
worldwide. The protozoan parasite has a relatively simple life cycle with two principal …
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to …
Background Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …
Anti-leishmanial activity of heteroleptic organometallic Sb (V) compounds
MI Ali, MK Rauf, A Badshah, I Kumar, CM Forsyth… - Dalton …, 2013 - pubs.rsc.org
In seeking new drugs for the treatment of the parasitic disease Leishmaniasis, an extensive
range of organometallic antimony (V) dicarboxylates of the form [SbR3 (O2CR′) 2] have …
range of organometallic antimony (V) dicarboxylates of the form [SbR3 (O2CR′) 2] have …
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis
V Bhandari, A Kulshrestha, DK Deep… - PLoS neglected …, 2012 - journals.plos.org
Background With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the
Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy …
Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy …
New trends in the use of aminoglycosides
Despite their inherent toxicity and the acquired bacterial resistance that continuously
threaten their long-term clinical use, aminoglycosides (AGs) still remain valuable …
threaten their long-term clinical use, aminoglycosides (AGs) still remain valuable …
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
V Wiwanitkit - Therapeutics and clinical risk management, 2012 - Taylor & Francis
Leishmaniasis is an important vector-borne disease, and it is classified as one of the most
important tropical fly-borne infections. This disease can cause two types of clinical …
important tropical fly-borne infections. This disease can cause two types of clinical …
Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani
Leishmania donovani is the causative agent of the potentially fatal disease visceral
leishmaniasis (VL). Chemotherapeutic options available to treat VL are limited and often …
leishmaniasis (VL). Chemotherapeutic options available to treat VL are limited and often …
Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects
Human visceral leishmaniasis (VL) continues to be a life-threatening neglected tropical
disease, with close to 200 million people at risk of infection globally. Epidemics and …
disease, with close to 200 million people at risk of infection globally. Epidemics and …
Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients
W Adriaensen, TPC Dorlo, G Vanham… - Frontiers in …, 2018 - frontiersin.org
Patients with visceral leishmaniasis (VL)–human immunodeficiency virus (HIV) coinfection
experience increased drug toxicity and treatment failure rates compared to VL patients, with …
experience increased drug toxicity and treatment failure rates compared to VL patients, with …